Tags : long-acting erythropoiesis


YL Biologics Reports the NDA Submission of YLB217 (biosimilar product

Shots: YLB reported the NDA filing of YLB217, a biosimilar product of long-acting erythropoiesis-stimulating agent Nesp, which YLB solely developed, was executed through Yoshindo On Sept 08, 2017, YLB signed a technology transfer agreement with CJ Healthcare, including exclusive development and marketing rights for Nesp biosimilar and started domestic development with the sponsorship of Yoshindo […]Read More